3-bromocytisine and Cognition-Disorders

3-bromocytisine has been researched along with Cognition-Disorders* in 1 studies

Other Studies

1 other study(ies) available for 3-bromocytisine and Cognition-Disorders

Article	Year
Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo eff Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia. Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Azabicyclo Compounds; Biological Availability; Cells, Cultured; Cognition Disorders; Epithelial Cells; Female; Hippocampus; Humans; Kidney; Microsomes, Liver; Nicotinic Agonists; Nootropic Agents; Oocytes; Oxazoles; Rats; Receptors, Nicotinic; Schizophrenia; Skin; Structure-Activity Relationship; Xenopus laevis	2010

Article

Year

Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders in schizophrenia: synthesis, SAR development, and in vivo eff

Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3

A novel alpha 7 nAChR agonist, 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (24, CP-810,123), has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions including schizophrenia and Alzheimer's disease. Compound 24 is a potent and selective compound with excellent pharmaceutical properties. In rodent, the compound displays high oral bioavailability and excellent brain penetration affording high levels of receptor occupancy and in vivo efficacy in auditory sensory gating and novel object recognition. The structural diversity of this compound and its preclinical in vitro and in vivo package support the hypothesis that alpha 7 nAChR agonists may have potential as a pharmacotherapy for the treatment of cognitive deficits in schizophrenia.

Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Azabicyclo Compounds; Biological Availability; Cells, Cultured; Cognition Disorders; Epithelial Cells; Female; Hippocampus; Humans; Kidney; Microsomes, Liver; Nicotinic Agonists; Nootropic Agents; Oocytes; Oxazoles; Rats; Receptors, Nicotinic; Schizophrenia; Skin; Structure-Activity Relationship; Xenopus laevis

2010